reports
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Cle...
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody - Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
MUSA MURPHY USA INC.
MOS MOSAIC COMPANY
HNRG HALLADOR ENERGY CO.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GT GOODYEAR TIRE & RUBBER COMPANY
FAST FASTENAL COMPANY
BGS B&G FOODS INC.
CNR. CANADIAN NATIONAL RAILWAY COMPANY
AGX ARGAN INC.
LEU CENTRUS ENERGY CORPORATION
GRPN GROUPON INC.
IPI INTREPID POTASH
SBTX SILVERBACK THERAPEUTICS
SDGR SCHRODINGER
RGC REGENCELL BIOSCIENCE HLDGS LTD
PPTA PERPETUA RESOURCES CORP
MPTI M TRON INDUSTRIES INC
ASPI ASP ISOTOPES INC
ANG ANGLOGOLD ASHANTI LIMITED
AZ A2Z CUST2MATE SOLUTIONS CORP
USAU US GOLD CORP
SLNO SOLENO THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
WU WESTERN UNION COMPANY
PZZA PAPA JOHN'S INTERNATIONAL INC.
LEN LENNAR CORPORATION CLASS A
KBH KB HOME
FAST FASTENAL COMPANY
CXW CORECIVIC INC.
ANDE ANDERSONS INC.
DHI D.R. HORTON INC.
TREE LENDINGTREE INC.
NC NACCO INDUSTRIES INC. CL A
TIGO MILLICOM INTERNATIONAL CELLULAR S.A.
WSTG WAYSIDE TECHNOLOGY
ALGM ALLEGRO MICROSYSTEMS
CSTM CONSTELLIUM SE CLASS A
Aclaris Therapeutics to Participate in Two March Healthcare Conference...
Aclaris Therapeutics to Participate in Two March Healthcare Conferences WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners ...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financi...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ’s Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runw...
New Publication Highlights Unique Properties of ATI-2138, a Potent and...
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics’ ATI-2138, a novel investigational covalent inhi...
Aclaris Therapeutics Announces Formation of New Scientific Advisory Bo...
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board (SAB), which initially includes experts in the field of pulmonology. These include Marianne Mann, M.D., and Zuzana Diamant, M.D., Ph.D. leading experts in respiratory medicine, clinical pharmacology, and immunology. "We are delighted to welco...
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing ...
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris’ Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employe...
Molecular Templates Announces Notice of Delisting and Failure to Satis...
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasda...
- Jonathan Moreland
- Jonathan Moreland
MYE MYERS INDUSTRIES INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
LTRX LANTRONIX INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
GLP GLOBAL PARTNERS LP
FCN FTI CONSULTING INC.
CVGI COMMERCIAL VEHICLE GROUP INC.
BRKR BRUKER CORPORATION
AXSM AXSOME THERAPEUTICS
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
ISTR INVESTAR HOLD
PETS PETMED EXPRESS INC.
FRD FRIEDMAN INDUSTRIES INC.
VVV VALVOLINE INC.
SACH SACHEM CAPITAL
DMLP DORCHESTER MINERALS L.P.
MBIN MERCHANTS BANCORP
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
FBRX FORTE BIOSCIENCES INC
VRM VROOM
ONEW INC.
SSSS ONEWATER MARINE
ABCL SUTTER ROCK CAPITAL CORP.
FTHM ABCELLERA BIOLOGICS
IMNM FATHOM HOLDINGS
WOLF IMMUNOME
CLVT WOLFSPEED INC
RWAY CLARIVATE PLC
ANTX RUNWAY GROWTH FINANCE CORP
NXGL AN2 THERAPEUTICS INC
HR NEXGEL INC
CARV HEALTHCARE TRUST OF AMERICA INC.
BIGZ CARVER BANCORP INC
MODD BLACKROCK INNOVATION AND GROWTH TST
PFHC MODULAR MEDICAL INC
GRNT PROFRAC HLDG CORP
NCDL GRANITE RIDGE RESOURCES INC
SPRU NUVEEN CHURCHILL DIRECT LENDING CORP
CATX SPRUCE POWER HOLDING CORP
ASMB PERSPECTIVE THERAPEUTICS
FGF INC.
GWAV ASSEMBLY BIOSCIENCES INC
FG FINANCIAL GROUP
INC.
GREENWAVE TECHNOLOGY SOLUTIONS INC
Molecular Templates Announces Receipt of Expected Notification of Defi...
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announc...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
MYE MYERS INDUSTRIES INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
LTRX LANTRONIX INC.
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
BRKR BRUKER CORPORATION
AXSM AXSOME THERAPEUTICS
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
ISTR INVESTAR HOLD
FRD FRIEDMAN INDUSTRIES INC.
SACH SACHEM CAPITAL
MBIN MERCHANTS BANCORP
LILA LIBERTY LATIN AMERICA A
FF FIRST MINING GOLD
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
FBRX FORTE BIOSCIENCES INC
TFC TRUIST FINANCIAL CORP
ONEW ONEWATER MARINE
ARRY ARRAY TECHNOLOGIES
SSSS SUTTER ROCK CAPITAL CORP.
ABCL ABCELLERA BIOLOGICS
CSU CAPITAL SENIOR LIVING
IMNM IMMUNOME
GRNT GRANIT SKOPKE
OSCR OSCAR HEALTH
WOLF WOLFSPEED INC
CLVT CLARIVATE PLC
ZETA ZETA GLOBAL HLDGS CORP
RWAY RUNWAY GROWTH FINANCE CORP
ANTX AN2 THERAPEUTICS INC
CGBD TCG BDC
NXGL INC.
HR NEXGEL INC
CARV HEALTHCARE TRUST OF AMERICA INC.
PFHC CARVER BANCORP INC
EP PROFRAC HLDG CORP
CATX EMPIRE PETROLEUM CORP
ASMB PERSPECTIVE THERAPEUTICS
DC INC.
FGF ASSEMBLY BIOSCIENCES INC
AGFY DAKOTA GOLD CORP.
FG FINANCIAL GROUP
INC.
AGRIFY CORPORATION
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual H...
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York. A webcast of the fireside chat may be accessed through the “Events” page...
- Jonathan Moreland
RMAX RE/MAX HOLDINGS INC.
PSEC PROSPECT CAPITAL CORPORATION
PPSI PIONEER POWER SOLUTIONS
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ANGI ANGI INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MBIN MERCHANTS BANCORP
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
BDSX BIODESIX
CSU CAPITAL SENIOR LIVING
MODV MODIVCARE INC
GRNT GRANIT SKOPKE
UAN CVR PARTNERS LP
INBX INHIBRX
OSCR INC.
WOLF OSCAR HEALTH
CLVT WOLFSPEED INC
ZETA CLARIVATE PLC
RWAY ZETA GLOBAL HLDGS CORP
CGBD RUNWAY GROWTH FINANCE CORP
NXGL TCG BDC
BIGZ INC.
DOUG NEXGEL INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
EP DOUGLAS ELLIMAN INC
MIO WK KELLOGG CO
MDRR EMPIRE PETROLEUM CORP
BNTC PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
FGF BENITEC BIOPHARMA INC
EATON VANCE INSD CALIF MUN BD FD
FG FINANCIAL GROUP
INC.
- Jonathan Moreland
RMAX RE/MAX HOLDINGS INC.
RGEN REPLIGEN CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
IRWD IRONWOOD PHARMACEUTICALS INC. CLASS A
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
AXSM AXSOME THERAPEUTICS
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
MBIN MERCHANTS BANCORP
FSLY FASTLY
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
RWAY RUNWAY GROWTH FINANCE CORP
HYLN HYLIION HOLDINGS CORP.
SYRS SYROS PHARMACEUTICALS INC.
Aclaris Therapeutics Announces $80 Million Private Placement
Aclaris Therapeutics Announces $80 Million Private Placement WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. The private placement is expect...
Aclaris Therapeutics Announces Exclusive, Global License Agreement wit...
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered ...
Fastenal Co: 5 directors
A director at Fastenal Co bought 104 shares at 0.000USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and ...
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update – First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an imp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.